A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC

von Christopoulos, Petros, Thomas, Michael
Veröffentlicht in J Thorac Dis (2017)

Therapeutic Sequencing in ALK(+) NSCLC

von Elsayed, Mei, Christopoulos, Petros
Veröffentlicht in Pharmaceuticals (Basel) (2021)

Breaking Bottlenecks for the TCR Therapy of Cancer

von Gaissmaier, Lena, Elshiaty, Mariam, Christopoulos, Petros
Veröffentlicht in Cells (2020)

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

von Elshiaty, Mariam, Schindler, Hannah, Christopoulos, Petros
Veröffentlicht in Int J Mol Sci (2021)

Stage IV malignant melanoma of unknown primary site in a young man

von Christopoulos, Petros, Doulias, Triantafyllos, Koutelidakis, Ioannis, Papaziogas, Bassileios
Veröffentlicht in BMJ Case Rep (2012)

EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK(+) NSCLC

von Christopoulos, Petros, Kirchner, Martina, Endris, Volker, Stenzinger, Albrecht, Thomas, Michael
Veröffentlicht in J Thorac Dis (2018)

Defining molecular risk in ALK(+) NSCLC

von Christopoulos, Petros, Budczies, Jan, Kirchner, Martina, Dietz, Steffen, Sültmann, Holger, Thomas, Michael, Stenzinger, Albrecht
Veröffentlicht in Oncotarget (2019)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

von Hohmann, Nicolas, Bozorgmehr, Farastuk, Christopoulos, Petros, Mikus, Gerd, Blank, Antje, Burhenne, Jürgen, Thomas, Michael, Haefeli, Walter E.
Veröffentlicht in Clin Transl Sci (2020)

Retroperitoneal Abscess Formation as a Result of Spilled Gallstones during Laparoscopic Cholecystectomy: An Unusual Case Report

von Chatzimavroudis, Grigoris, Atmatzidis, Stefanos, Papaziogas, Basilis, Galanis, Ioannis, Koutelidakis, Ioannis, Doulias, Triantafyllos, Christopoulos, Petros, Papadakis, George, Atmatzidis, Konstantinos, Makris, John
Veröffentlicht 2012

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden

von Budczies, Jan, Seidel, Anja, Christopoulos, Petros, Endris, Volker, Kloor, Matthias, Győrffy, Balázs, Seliger, Barbara, Schirmacher, Peter, Stenzinger, Albrecht, Denkert, Carsten
Veröffentlicht in Oncoimmunology (2018)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durval...

von Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Veröffentlicht in BMC Cancer (2020)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis

von Eichhorn, Florian, Kriegsmann, Mark, Klotz, Laura V., Kriegsmann, Katharina, Muley, Thomas, Zgorzelski, Christiane, Christopoulos, Petros, Winter, Hauke, Eichhorn, Martin E.
Veröffentlicht in Cancers (Basel) (2021)

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition

von Baum, Philip, Taber, Samantha, Erdmann, Stella, Muley, Thomas, Kriegsmann, Mark, Christopoulos, Petros, Thomas, Michael, Winter, Hauke, Pfannschmidt, Joachim, Eichhorn, Martin E.
Veröffentlicht in Cancers (Basel) (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

von Elsayed, Mei, Bozorgmehr, Farastuk, Kazdal, Daniel, Volckmar, Anna-Lena, Sültmann, Holger, Fischer, Jürgen R., Kriegsmann, Mark, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Veröffentlicht in Front Oncol (2021)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protoco...

von Christopoulos, Petros, Bozorgmehr, Farastuk, Brückner, Lena, Chung, Inn, Krisam, Johannes, Schneider, Marc A., Stenzinger, Albrecht, Eickhoff, Regina, Mueller, Daniel W., Thomas, Michael
Veröffentlicht in BMC Cancer (2021)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC

von Richtmann, Sarah, Wilkens, Dennis, Warth, Arne, Lasitschka, Felix, Winter, Hauke, Christopoulos, Petros, Herth, Felix J. F., Muley, Thomas, Meister, Michael, Schneider, Marc A.
Veröffentlicht in Cancers (Basel) (2019)

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients

von von Eiff, Damian, Bozorgmehr, Farastuk, Chung, Inn, Bernhardt, Denise, Rieken, Stefan, Liersch, Stephan, Muley, Thomas, Kobinger, Sonja, Thomas, Michael, Christopoulos, Petros, Steins, Martin
Veröffentlicht in J Thorac Dis (2020)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Cas...

von Blasi, Miriam, Kazdal, Daniel, Thomas, Michael, Christopoulos, Petros, Kriegsmann, Mark, Brandt, Regine, Volckmar, Anna-Lena, Kirchner, Martina, Heußel, Claus Peter, Stenzinger, Albrecht, Kuon, Jonas
Veröffentlicht in Case Rep Oncol (2021)

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients

von Schneider, Marc A., Christopoulos, Petros, Muley, Thomas, Warth, Arne, Klingmueller, Ursula, Thomas, Michael, Herth, Felix J.F., Dienemann, Hendrik, Mueller, Nikola S., Theis, Fabian, Meister, Michael
Veröffentlicht in Int J Oncol (2017)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

von Faehling, Martin, Schumann, Christian, Christopoulos, Petros, Hoffknecht, Petra, Alt, Jürgen, Horn, Marlitt, Eisenmann, Stephan, Schlenska-Lange, Anke, Schütt, Philipp, Steger, Felix, Brückl, Wolfgang M., Christoph, Daniel C.
Veröffentlicht in Data Brief (2020)